SFr. 355.00
€ 383.40
BTC 0.0069
LTC 6.94
ETH 0.1708


bestellen

Artikel-Nr. 14778694


Diesen Artikel in meine
Wunschliste
Diesen Artikel
weiterempfehlen
Diesen Preis
beobachten

Weitersagen:


Herausgeber: 
  • Dale L. Oxender
  • Leonard E. Post
  • Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing 
     

    (Buch)
    Dieser Artikel gilt, aufgrund seiner Grösse, beim Versand als 2 Artikel!


    Übersicht

    Auf mobile öffnen
     
    Lieferstatus:   i.d.R. innert 5-10 Tagen versandfertig
    Veröffentlichung:  Juli 1999  
    Genre:  Naturwissensch., Medizin, Technik 
    ISBN:  9783540659273 
    EAN-Code: 
    9783540659273 
    Verlag:  Springer Berlin Heidelberg 
    Einband:  Kartoniert  
    Sprache:  English  
    Dimensionen:  H 235 mm / B 155 mm / D 15 mm 
    Gewicht:  417 gr 
    Seiten:  272 
    Zus. Info:  Paperback 
    Bewertung: Titel bewerten / Meinung schreiben
    Inhalt:
    A cover story of Business Week Magazine in January 1984 stated "Biotech Comes of Age". In February 1986, Venture Magazine had a cover article entitled "The Biotech Revolution is Here". This article went on to say "New Genetic Technologies Will Transform Our Lives". These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed-to commercialize the "New Biology". . At the time of writing this book, there are over 1300 biotech companies developing new technologies or identifying potential biotech drugs. Most of these companies were started in the height of the "high-technology hype", although companies are still forming as the technology advances. A more recent survey showed only a relatively small number of Food and Drug Administration (FDA) approvals among over several hundred biotech­ nology products now in clinical trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, such as peptides, proteins, monoclonal antibodies, nucleic acids and cellular therapies.

      



    Wird aktuell angeschaut...
     

    Zurück zur letzten Ansicht


    AGB | Datenschutzerklärung | Mein Konto | Impressum | Partnerprogramm
    Newsletter | 1Advd.ch RSS News-Feed Newsfeed | 1Advd.ch Facebook-Page Facebook | 1Advd.ch Twitter-Page Twitter
    Forbidden Planet AG © 1999-2024
    Alle Angaben ohne Gewähr
     
    SUCHEN

     
     Kategorien
    Im Sortiment stöbern
    Genres
    Hörbücher
    Aktionen
     Infos
    Mein Konto
    Warenkorb
    Meine Wunschliste
     Kundenservice
    Recherchedienst
    Fragen / AGB / Kontakt
    Partnerprogramm
    Impressum
    © by Forbidden Planet AG 1999-2024